Is DocuSign Stock Undervalued?
Digital signature software business DocuSign (NASDAQ:DOCU) has been struggling over…
Sell
25
HOWL Quote, Financials, Valuation and Earnings
Last price:
$0.61
Seasonality move
:
10.2%
Day range:
$0.61 - $0.67
52-week range:
$0.56 - $2.38
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
52.13x
P/B ratio:
1.07x
Volume:
670K
Avg. volume:
765.7K
1-year change:
-58.85%
Market cap:
$31.8M
Revenue:
$1.9M
EPS (TTM):
-$1.62
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
HOWL
Werewolf Therapeutics, Inc.
|
-- | -$0.38 | -100% | -24.23% | $5.20 |
|
ALNY
Alnylam Pharmaceuticals, Inc.
|
$974.1M | $1.75 | 98.51% | -58.59% | $491.92 |
|
ANIP
ANI Pharmaceuticals, Inc.
|
$212.9M | $1.77 | 22.43% | 68.6% | $109.25 |
|
BMRN
BioMarin Pharmaceutical, Inc.
|
$780.4M | $0.34 | 11.37% | 43.52% | $89.74 |
|
INSM
Insmed, Inc.
|
$115.5M | -$1.37 | 66.86% | -2.57% | $214.78 |
|
VKTX
Viking Therapeutics, Inc.
|
-- | -$0.67 | -- | -182.02% | $93.39 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
HOWL
Werewolf Therapeutics, Inc.
|
$0.65 | $5.20 | $31.8M | -- | $0.00 | 0% | 52.13x |
|
ALNY
Alnylam Pharmaceuticals, Inc.
|
$400.59 | $491.92 | $52.9B | 1,665.65x | $0.00 | 0% | 16.43x |
|
ANIP
ANI Pharmaceuticals, Inc.
|
$82.41 | $109.25 | $1.9B | 50.54x | $0.00 | 0% | 2.02x |
|
BMRN
BioMarin Pharmaceutical, Inc.
|
$59.95 | $89.74 | $11.5B | 22.46x | $0.00 | 0% | 3.80x |
|
INSM
Insmed, Inc.
|
$177.88 | $214.78 | $37.9B | -- | $0.00 | 0% | 75.70x |
|
VKTX
Viking Therapeutics, Inc.
|
$37.18 | $93.39 | $4.2B | -- | $0.00 | 0% | -- |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
HOWL
Werewolf Therapeutics, Inc.
|
55.74% | 4.232 | 40.05% | 3.73x |
|
ALNY
Alnylam Pharmaceuticals, Inc.
|
92.22% | 1.279 | 4.61% | 2.37x |
|
ANIP
ANI Pharmaceuticals, Inc.
|
55.53% | -0.550 | 30.7% | 2.40x |
|
BMRN
BioMarin Pharmaceutical, Inc.
|
9.17% | -0.764 | 5.87% | 2.84x |
|
INSM
Insmed, Inc.
|
44.07% | 2.512 | 2.43% | 4.18x |
|
VKTX
Viking Therapeutics, Inc.
|
0.11% | 1.448 | 0.03% | 27.41x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
HOWL
Werewolf Therapeutics, Inc.
|
-$402K | -$15.7M | -76.44% | -125.09% | -1409.19% | -$15.2M |
|
ALNY
Alnylam Pharmaceuticals, Inc.
|
$1B | $368M | 1.51% | 31.15% | 29.46% | $313M |
|
ANIP
ANI Pharmaceuticals, Inc.
|
$111.8M | $22.8M | 3.31% | 8.22% | 10.02% | $37.9M |
|
BMRN
BioMarin Pharmaceutical, Inc.
|
$641.8M | $184.9M | 8.12% | 8.99% | 23.5% | $334.9M |
|
INSM
Insmed, Inc.
|
$111.4M | -$261.4M | -70.98% | -193.23% | -183.61% | -$222.2M |
|
VKTX
Viking Therapeutics, Inc.
|
-$114K | -$98.6M | -28.59% | -28.62% | -- | -$94M |
Werewolf Therapeutics, Inc. vs. Competitors
-
Which has Higher Returns HOWL or ALNY?
Alnylam Pharmaceuticals, Inc. has a net margin of -1509.1% compared to Werewolf Therapeutics, Inc.'s net margin of 20.1%. Werewolf Therapeutics, Inc.'s return on equity of -125.09% beat Alnylam Pharmaceuticals, Inc.'s return on equity of 31.15%.
Company Gross Margin Earnings Per Share Invested Capital HOWLWerewolf Therapeutics, Inc.-- -$0.36 $66.9M ALNYAlnylam Pharmaceuticals, Inc.83.98% $1.84 $3B -
What do Analysts Say About HOWL or ALNY?
Werewolf Therapeutics, Inc. has a consensus price target of $5.20, signalling upside risk potential of 694.74%. On the other hand Alnylam Pharmaceuticals, Inc. has an analysts' consensus of $491.92 which suggests that it could grow by 22.8%. Given that Werewolf Therapeutics, Inc. has higher upside potential than Alnylam Pharmaceuticals, Inc., analysts believe Werewolf Therapeutics, Inc. is more attractive than Alnylam Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings HOWLWerewolf Therapeutics, Inc.4 2 0 ALNYAlnylam Pharmaceuticals, Inc.14 7 0 -
Is HOWL or ALNY More Risky?
Werewolf Therapeutics, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Alnylam Pharmaceuticals, Inc. has a beta of 0.301, suggesting its less volatile than the S&P 500 by 69.879%.
-
Which is a Better Dividend Stock HOWL or ALNY?
Werewolf Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Alnylam Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Werewolf Therapeutics, Inc. pays -- of its earnings as a dividend. Alnylam Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios HOWL or ALNY?
Werewolf Therapeutics, Inc. quarterly revenues are --, which are smaller than Alnylam Pharmaceuticals, Inc. quarterly revenues of $1.2B. Werewolf Therapeutics, Inc.'s net income of -$16.4M is lower than Alnylam Pharmaceuticals, Inc.'s net income of $251.1M. Notably, Werewolf Therapeutics, Inc.'s price-to-earnings ratio is -- while Alnylam Pharmaceuticals, Inc.'s PE ratio is 1,665.65x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Werewolf Therapeutics, Inc. is 52.13x versus 16.43x for Alnylam Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income HOWLWerewolf Therapeutics, Inc.52.13x -- -- -$16.4M ALNYAlnylam Pharmaceuticals, Inc.16.43x 1,665.65x $1.2B $251.1M
-
Which has Higher Returns HOWL or ANIP?
ANI Pharmaceuticals, Inc. has a net margin of -1509.1% compared to Werewolf Therapeutics, Inc.'s net margin of 10.59%. Werewolf Therapeutics, Inc.'s return on equity of -125.09% beat ANI Pharmaceuticals, Inc.'s return on equity of 8.22%.
Company Gross Margin Earnings Per Share Invested Capital HOWLWerewolf Therapeutics, Inc.-- -$0.36 $66.9M ANIPANI Pharmaceuticals, Inc.49.07% $1.13 $1.1B -
What do Analysts Say About HOWL or ANIP?
Werewolf Therapeutics, Inc. has a consensus price target of $5.20, signalling upside risk potential of 694.74%. On the other hand ANI Pharmaceuticals, Inc. has an analysts' consensus of $109.25 which suggests that it could grow by 32.57%. Given that Werewolf Therapeutics, Inc. has higher upside potential than ANI Pharmaceuticals, Inc., analysts believe Werewolf Therapeutics, Inc. is more attractive than ANI Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings HOWLWerewolf Therapeutics, Inc.4 2 0 ANIPANI Pharmaceuticals, Inc.4 1 0 -
Is HOWL or ANIP More Risky?
Werewolf Therapeutics, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison ANI Pharmaceuticals, Inc. has a beta of 0.484, suggesting its less volatile than the S&P 500 by 51.639%.
-
Which is a Better Dividend Stock HOWL or ANIP?
Werewolf Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. ANI Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Werewolf Therapeutics, Inc. pays -- of its earnings as a dividend. ANI Pharmaceuticals, Inc. pays out 8.77% of its earnings as a dividend. ANI Pharmaceuticals, Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios HOWL or ANIP?
Werewolf Therapeutics, Inc. quarterly revenues are --, which are smaller than ANI Pharmaceuticals, Inc. quarterly revenues of $227.8M. Werewolf Therapeutics, Inc.'s net income of -$16.4M is lower than ANI Pharmaceuticals, Inc.'s net income of $24.1M. Notably, Werewolf Therapeutics, Inc.'s price-to-earnings ratio is -- while ANI Pharmaceuticals, Inc.'s PE ratio is 50.54x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Werewolf Therapeutics, Inc. is 52.13x versus 2.02x for ANI Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income HOWLWerewolf Therapeutics, Inc.52.13x -- -- -$16.4M ANIPANI Pharmaceuticals, Inc.2.02x 50.54x $227.8M $24.1M
-
Which has Higher Returns HOWL or BMRN?
BioMarin Pharmaceutical, Inc. has a net margin of -1509.1% compared to Werewolf Therapeutics, Inc.'s net margin of -3.91%. Werewolf Therapeutics, Inc.'s return on equity of -125.09% beat BioMarin Pharmaceutical, Inc.'s return on equity of 8.99%.
Company Gross Margin Earnings Per Share Invested Capital HOWLWerewolf Therapeutics, Inc.-- -$0.36 $66.9M BMRNBioMarin Pharmaceutical, Inc.81.58% -$0.16 $6.7B -
What do Analysts Say About HOWL or BMRN?
Werewolf Therapeutics, Inc. has a consensus price target of $5.20, signalling upside risk potential of 694.74%. On the other hand BioMarin Pharmaceutical, Inc. has an analysts' consensus of $89.74 which suggests that it could grow by 49.69%. Given that Werewolf Therapeutics, Inc. has higher upside potential than BioMarin Pharmaceutical, Inc., analysts believe Werewolf Therapeutics, Inc. is more attractive than BioMarin Pharmaceutical, Inc..
Company Buy Ratings Hold Ratings Sell Ratings HOWLWerewolf Therapeutics, Inc.4 2 0 BMRNBioMarin Pharmaceutical, Inc.13 7 0 -
Is HOWL or BMRN More Risky?
Werewolf Therapeutics, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison BioMarin Pharmaceutical, Inc. has a beta of 0.299, suggesting its less volatile than the S&P 500 by 70.071%.
-
Which is a Better Dividend Stock HOWL or BMRN?
Werewolf Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. BioMarin Pharmaceutical, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Werewolf Therapeutics, Inc. pays -- of its earnings as a dividend. BioMarin Pharmaceutical, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios HOWL or BMRN?
Werewolf Therapeutics, Inc. quarterly revenues are --, which are smaller than BioMarin Pharmaceutical, Inc. quarterly revenues of $786.8M. Werewolf Therapeutics, Inc.'s net income of -$16.4M is higher than BioMarin Pharmaceutical, Inc.'s net income of -$30.7M. Notably, Werewolf Therapeutics, Inc.'s price-to-earnings ratio is -- while BioMarin Pharmaceutical, Inc.'s PE ratio is 22.46x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Werewolf Therapeutics, Inc. is 52.13x versus 3.80x for BioMarin Pharmaceutical, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income HOWLWerewolf Therapeutics, Inc.52.13x -- -- -$16.4M BMRNBioMarin Pharmaceutical, Inc.3.80x 22.46x $786.8M -$30.7M
-
Which has Higher Returns HOWL or INSM?
Insmed, Inc. has a net margin of -1509.1% compared to Werewolf Therapeutics, Inc.'s net margin of -259.95%. Werewolf Therapeutics, Inc.'s return on equity of -125.09% beat Insmed, Inc.'s return on equity of -193.23%.
Company Gross Margin Earnings Per Share Invested Capital HOWLWerewolf Therapeutics, Inc.-- -$0.36 $66.9M INSMInsmed, Inc.78.29% -$1.75 $1.7B -
What do Analysts Say About HOWL or INSM?
Werewolf Therapeutics, Inc. has a consensus price target of $5.20, signalling upside risk potential of 694.74%. On the other hand Insmed, Inc. has an analysts' consensus of $214.78 which suggests that it could grow by 20.84%. Given that Werewolf Therapeutics, Inc. has higher upside potential than Insmed, Inc., analysts believe Werewolf Therapeutics, Inc. is more attractive than Insmed, Inc..
Company Buy Ratings Hold Ratings Sell Ratings HOWLWerewolf Therapeutics, Inc.4 2 0 INSMInsmed, Inc.17 1 0 -
Is HOWL or INSM More Risky?
Werewolf Therapeutics, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Insmed, Inc. has a beta of 1.015, suggesting its more volatile than the S&P 500 by 1.49%.
-
Which is a Better Dividend Stock HOWL or INSM?
Werewolf Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Insmed, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Werewolf Therapeutics, Inc. pays -- of its earnings as a dividend. Insmed, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios HOWL or INSM?
Werewolf Therapeutics, Inc. quarterly revenues are --, which are smaller than Insmed, Inc. quarterly revenues of $142.3M. Werewolf Therapeutics, Inc.'s net income of -$16.4M is higher than Insmed, Inc.'s net income of -$370M. Notably, Werewolf Therapeutics, Inc.'s price-to-earnings ratio is -- while Insmed, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Werewolf Therapeutics, Inc. is 52.13x versus 75.70x for Insmed, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income HOWLWerewolf Therapeutics, Inc.52.13x -- -- -$16.4M INSMInsmed, Inc.75.70x -- $142.3M -$370M
-
Which has Higher Returns HOWL or VKTX?
Viking Therapeutics, Inc. has a net margin of -1509.1% compared to Werewolf Therapeutics, Inc.'s net margin of --. Werewolf Therapeutics, Inc.'s return on equity of -125.09% beat Viking Therapeutics, Inc.'s return on equity of -28.62%.
Company Gross Margin Earnings Per Share Invested Capital HOWLWerewolf Therapeutics, Inc.-- -$0.36 $66.9M VKTXViking Therapeutics, Inc.-- -$0.81 $713.8M -
What do Analysts Say About HOWL or VKTX?
Werewolf Therapeutics, Inc. has a consensus price target of $5.20, signalling upside risk potential of 694.74%. On the other hand Viking Therapeutics, Inc. has an analysts' consensus of $93.39 which suggests that it could grow by 151.18%. Given that Werewolf Therapeutics, Inc. has higher upside potential than Viking Therapeutics, Inc., analysts believe Werewolf Therapeutics, Inc. is more attractive than Viking Therapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings HOWLWerewolf Therapeutics, Inc.4 2 0 VKTXViking Therapeutics, Inc.12 1 0 -
Is HOWL or VKTX More Risky?
Werewolf Therapeutics, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Viking Therapeutics, Inc. has a beta of 0.649, suggesting its less volatile than the S&P 500 by 35.072%.
-
Which is a Better Dividend Stock HOWL or VKTX?
Werewolf Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Viking Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Werewolf Therapeutics, Inc. pays -- of its earnings as a dividend. Viking Therapeutics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios HOWL or VKTX?
Werewolf Therapeutics, Inc. quarterly revenues are --, which are smaller than Viking Therapeutics, Inc. quarterly revenues of --. Werewolf Therapeutics, Inc.'s net income of -$16.4M is higher than Viking Therapeutics, Inc.'s net income of -$90.8M. Notably, Werewolf Therapeutics, Inc.'s price-to-earnings ratio is -- while Viking Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Werewolf Therapeutics, Inc. is 52.13x versus -- for Viking Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income HOWLWerewolf Therapeutics, Inc.52.13x -- -- -$16.4M VKTXViking Therapeutics, Inc.-- -- -- -$90.8M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is SentinelOne Stock Undervalued?
Cybersecurity major SentinelOne (NYSE:S) has struggled over several years, delivering…
Is Broadcom Stock on Sale?
Chip and software maker Broadcom (NASDAQ:AVGO) has been among the…
Stock Ideas
Buy
59
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 65x
Buy
55
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 37x
Buy
61
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 39x
Alerts
Buy
72
GLTO alert for Dec 29
Galecto, Inc. [GLTO] is down 12.13% over the past day.
Sell
20
SMX alert for Dec 29
SMX (Security Matters) Plc [SMX] is down 27.67% over the past day.
Sell
11
CDNAF alert for Dec 29
Canadian Tire Corp. Ltd. [CDNAF] is up 11.94% over the past day.
